Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

NCT01451268 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

DRUG: Panobinostat
DRUG: Panobinostat

Sponsor

Johann Wolfgang Goethe University Hospital